Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 654

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI

Open access
Claassens, Daniel M.F., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean-Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Postma, Maarten J., de Boer, Anthonius, Boersma, Cornelis, Deneer, Vera H.M., ten Berg, Jurriën M.·2019·New England Journal of Medicine

Abstract

BACKGROUND: inhibitors. METHODS: *3 loss-of-function alleles received ticagrelor or prasugrel, and noncarriers received clopidogrel. The two primary outcomes were net adverse clinical events - defined as death from any cause, myocardial infarction, definite stent thrombosis, stroke, or major bleeding defined according to Platelet Inhibition and Patient Outcomes (PLATO) criteria - at 12 months (primary combined outcome; tested for noninferiority, with a noninferiority margin of 2 percentage points for the absolute difference) and PLATO major or minor bleeding at 12 months (primary bleeding outcome). RESULTS: For the primary analysis, 2488 patients were included: 1242 in the genotype-guided group and 1246 in the standard-treatment group. The primary combined outcome occurred in 63 patients (5.1%) in the genotype-guided group and in 73 patients (5.9%) in the standard-treatment group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.0 to 0.7; P<0.001 for noninferiority). The primary bleeding outcome occurred in 122 patients (9.8%) in the genotype-guided group and in 156 patients (12.5%) in the standard-treatment group (hazard ratio, 0.78; 95% CI, 0.61 to 0.98; P = 0.04). CONCLUSIONS: inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics ClinicalTrials.gov number, NCT01761786; Netherlands Trial Register number, NL2872.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1907096

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 654

Metadata

Authors
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van ’t Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., Mosterd, A., Herrman, J.-P. R., Dewilde, W. J. M., Janssen, P. W. A., Kelder, J. C., Postma, M. J., de Boer, A., Boersma, C., Deneer, V. H. M., & ten Berg, J. M.
Venue
New England Journal of Medicine
Published
2019-10-24
Volume
381
Issue
17
Pages
1621-1631
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2971992346
Cited by
654
References
32
FWCI
55.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI. https://app.cochat.ai/papers/10.1056/nejmoa1907096
The paper
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van ’t Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., Mosterd, A., Herrman, J.-P. R., Dewilde, W. J. M., Janssen, P. W. A., Kelder, J. C., Postma, M. J., de Boer, A., Boersma, C., Deneer, V. H. M., & ten Berg, J. M. (2019). A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1907096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.